Concord Biotech: This niche API play rides on China-plus theme

Anubhav Sahu • September 28, 2023 / 14:29 IST

The company has a good repute in the fermentation-based API segment. A number of fermentation-based biologic drugs are expected to lose exclusivity in the next two years, and this opens a $60 billion opportunity.

Concord Biotech has had a smart entry into the secondary market, with a post-listing rally of 35 percent within six weeks

To read the full story,

Subscribe to Moneycontrol PRO

Ad-free Experience
Access Exclusive Stories
Weekly Investment Ideas
Daily Technical Calls

Are you a PRO subscriber? Sign In

What Do You Get

Ad free Experience

Seamless navigation, faster responses.
Expert Perspective

Explore 230+ exclusive editorials every month
+

Uncover Insights from World-Renowned Experts and Journalists
Actionable Insights

40+ weekly investment ideas + 3 to 4 daily technical calls
Virtual Events

Exclusive Live Webinars for Expert Trading & Investment Strategies!
Newsletters

Stay ahead with daily and weekly insights

View Offers

Unlock exclusive discounts

Disclosure & Disclaimer

This Research Report / Research Recommendation has been published by Moneycontrol Dot Com India Limited (hereinafter referred to as “MCD”) which is a registered Investment Advisor under the Securities and Exchange Board of India (Investment Advisers) ...Read More

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Concord Biotech: This niche API play rides on China-plus theme

The company has a good repute in the fermentation-based API segment. A number of fermentation-based biologic drugs are expected to lose exclusivity in the next two years, and this opens a $60 billion opportunity.

What Do You Get